為什麼腫瘤首次人體試驗在開始前就可能失敗
關於場地組合、方案假設、啟動延遲和隱藏執行風險的觀點。
洞察
早期腫瘤開發中，哪些訊號值得先看？
這裡整理公開研究、腫瘤會議訊號和我們對 FIH 執行風險的觀點。Apex AI 公開研究索引和 ASCO、ESMO、AACR、SITC 等官方來源會作為可篩選的資訊補充，所有卡片保留原始公開連結。
重點觀點
先看那些申辦方通常發現得太晚的問題。
這些固定主題讓洞察頁先有清楚判斷：外部公開來源能同步時作為補充，無法同步時頁面也不會變成空的資訊庫。
場地級啟動風險與傳統可行性評估
為什麼平均值和聲譽型專家選擇可能錯過真正重要的執行尾部風險。
中國創新藥如何進入全球開發語境
全球開發策略、區域選擇和試驗設計如何影響中國以外市場的可信度。
腫瘤場地選擇應如何按機制區分
ADC、雙抗、KRAS、CAR-T、放射性配體、DDR 資產和 TKI 不應使用同一套場地邏輯。
公開資訊庫
公開研究與腫瘤會議訊號
把 Apex AI 公開研究索引和 ASCO、ESMO、AACR、SITC 等官方公開來源放在同一個列表裡。可按來源、主題和關鍵詞篩選；所有卡片只保留公開後設資料和官方原始連結。
部分同步：ASCO Publications、SITC News Releases、SITC Annual Meeting 暫時無法使用。
當前來源：全部來源 · 主題：全部主題 · 25 條 · 每頁 10 條
Call for Submissions: 2027 AACR June L. Biedler Prize for Cancer Journalism
The AACR is inviting journalists to submit their stories for the 2027 AACR June L. Biedler Prize for Cancer Journalism. OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
檢視官方來源
AACR Applauds Bipartisan Senate Provision to Delay Harmful OMB Grantmaking Rule
PHILADELPHIA – The American Association for Cancer Research (AACR) commends Senate appropriators for including a bipartisan provision in its version of the fiscal year (FY) 2027 continuing resolution (CR) that... OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
檢視官方來源AACR Center for Cancer Clinical Trials Announces First Patient Enrolled in Phase II Clinical Trial for Locally Advanced Gastroeso...
PHILADELPHIA – The AACR Center for Cancer Clinical Trials, led by the American Association for Cancer Research (AACR), today announced that the AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastro... OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
檢視官方來源
A Vaccine to Prevent Pancreatic Cancer in High-risk Individuals Was Safe and Elicited Durable Immune Responses
After a median follow-up of 16.5 months, none of the participants developed pancreatic cancer, and some of the precancerous lesions shrank or stopped growing. OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
檢視官方來源Men May Be More Likely Than Women to Receive Later-stage Diagnoses for Many Cancer Types in the United States
Researchers say the study’s findings, published in Cancer Epidemiology, Biomarkers & Prevention, could provide insight into the discrepancies in cancer outcomes between men and women. OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
檢視官方來源
AACR Statement and Call to Action Concerning OMB Proposal to Rewrite the Rules for Scientists and Physicians Who Are Improving Pu...
The American Association for Cancer Research (AACR) is deeply concerned that the recent action of the White House Office of Management and Budget (OMB) to propose a new set of regulations on how federal grants... OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
檢視官方來源AACR Names Matthew Vander Heiden, MD, PhD, FAACR, as Editor-in-Chief of the Journal Cancer Discovery
The American Association for Cancer Research (AACR) has appointed Matthew Vander Heiden, MD, PhD, FAACR, as editor-in-chief of Cancer Discovery. OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
檢視官方來源AACR Releases Cancer Disparities Progress Report 2026
The report features latest statistics, including promising signs of progress, and 10 compelling personal stories. OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
檢視官方來源ASCO 2026 泌尿生殖肿瘤 — 摄护腺、膀胱、肾脏
按癌别整理 ASCO 2026 的摄护腺、膀胱、肾脏癌研究，含试验人数、HR、反应率与数据表。
檢視 AAI 原始來源ASCO 2026 的 AI:从研究主题到工具
AI 标记了 220 篇,是 ASCO 2026 最大的次分类。多数被用在具体任务上;试验匹配是它最直接碰到药物开发的一块。
檢視 AAI 原始來源